https://scholars.lib.ntu.edu.tw/handle/123456789/568634
標題: | Pegylated interferon α-2a versus standard interferon α-2a for treatment-naïve dialysis patients with chronic hepatitis C: A randomised study | 作者: | CHEN-HUA LIU Liang C.-C. JOU-WEI LIN Chen S.-I. Tsai H.-B. Chang C.-S. Hung P.-H. JIA-HORNG KAO CHUN-JEN LIU Lai M.-Y. Chen J.-H. PEI-JER CHEN DING-SHINN CHEN |
公開日期: | 2008 | 出版社: | BMJ Publishing Group | 卷: | 57 | 期: | 4 | 起(迄)頁: | 525-530 | 來源出版物: | Gut | 摘要: | Background: Chronic hepatitis C virus (HCV) infection is prevalent in dialysis patients, and standard interferon monotherapy is the current standard of care for such patients. Aim: To investigate whether pegylated interferon has a better therapeutic efficacy and safety profile than standard interferon in dialysis patients with chronic hepatitis C. Methods: 50 such patients were randomly assigned to receive either pegylated interferon α-2a 135 μg subcutaneously once per week or standard interferon α-2a 3 million units subcutaneously thrice per week for 24 weeks. The primary efficacy and safety end points were sustained virological response (SVR) by intention-to-treat analysis and treatment-related withdrawal rate during the study. Results: In univariate analysis, patients receiving pegylated interferon α-2a tended to have a higher sustained virological response (SVR) than those receiving standard interferon α-2a (48% vs 20%, p = 0.07). By using multivariate analysis, treatment with pegylated interferon α-2a (p = 0.02) and pretreatment HCV RNA level <800 000 IU/ml (p = 0.007) were independently predictive of an SVR. All patients failing to achieve a rapid virological response (RVR) could not achieve an SVR. In addition, patients receiving pegylated interferon α-2a had a significantly lower treatment-related withdrawal rate than those receiving standard interferon α-2a (0% vs 20%, p = 0.04). Conclusions: Pegylated interferon α-2a once weekly provides more effective and safer therapy than standard interferon α-2a thrice weekly for treatment-na?ve dialysis patients with chronic hepatitis C. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-41149086703&doi=10.1136%2fgut.2007.133884&partnerID=40&md5=9e3d311a19eecdbdf86e07dfc830149a https://scholars.lib.ntu.edu.tw/handle/123456789/568634 |
ISSN: | 0017-5749 | DOI: | 10.1136/gut.2007.133884 | SDG/關鍵字: | alpha2a interferon; peginterferon alpha2a; recombinant alpha2a interferon; alpha2a interferon; macrogol derivative; peginterferon alfa-2a; peginterferon alpha2a; unclassified drug; adult; alopecia; anorexia; article; clinical article; clinical trial; constipation; controlled clinical trial; controlled study; coughing; depression; dermatitis; diarrhea; dizziness; drug efficacy; drug fatality; drug safety; drug withdrawal; fatigue; female; fever; headache; hemodialysis patient; hepatitis C; human; injection site reaction; insomnia; irritability; leukopenia; male; monotherapy; multicenter study; multivariate analysis; myalgia; neutropenia; priority journal; randomized controlled trial; retina hemorrhage; rigor; side effect; thrombocytopenia; treatment outcome; univariate analysis; vomiting; comparative study; drug administration; middle aged; pathology; renal replacement therapy; virology; virus load; Adult; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon Alfa-2a; Male; Middle Aged; Polyethylene Glycols; Renal Dialysis; Treatment Outcome; Viral Load |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。